Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | VP Product Development | March 23, 2018 | March 27, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date March 23, 2018 · Filed March 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 558 |
Ending reported balance
After 2018-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-03-23 · Exercise / conversion · Acquired 1,750 · Balance 2,308 Row 2 · 2018-03-23 · Sale · Disposed 1,750 · Balance 558 F1: This transaction was executed in multiple trades at prices ranging from $33.12 to $32.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.60 · Expires 2018-06-30 | Direct | 10,438 |
Reported balance
After 2018-03-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-23 · Exercise / conversion · Disposed 1,750 · Balance 10,438 F2: The option is fully exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $33.12 to $32.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The option is fully exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2018 Filed Mar 27, 2018 17:40 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,750 | $0.00 Strike: $21.60 | $0.00 |
DisclosureSEC source: 0001209191-18-021805 · doc4.xml · derivative · entry 3 Lu Zhongjin · CIK 0001640691 · VP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,438 Underlying: Common Stock · 1,750 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully exercisable as of the date hereof. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:40 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | SaleCommon Stock | 1,750 | $32.74 | $57,295.00 |
DisclosureSEC source: 0001209191-18-021805 · doc4.xml · nonDerivative · entry 2 Lu Zhongjin · CIK 0001640691 · VP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558 F1 · price: This transaction was executed in multiple trades at prices ranging from $33.12 to $32.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:40 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | Exercise / conversionCommon Stock | 1,750 | $21.60 | $37,800.00 |
DisclosureSEC source: 0001209191-18-021805 · doc4.xml · nonDerivative · entry 1 Lu Zhongjin · CIK 0001640691 · VP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 12:12 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | SaleCommon Stock | 5,950 | $0.23 | $1,356.60 |
DisclosureSEC source: 0001209191-17-061940 · doc4.xml · nonDerivative · entry 1 Lu Zhongjin · CIK 0001640691 · VP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,153 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.225 to $0.233. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 19:14 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-17-039014 · doc4.xml · derivative · entry 2 Lu Zhongjin · CIK 0001640691 · VP Product Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-08 F2 · shares: 25% of the total number of shares subject to the Option will vest on the first anniversary of the date of the award; the remaining 75% will vest in 36 equal installments, subject to the Participant's continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.